Clinical Trial of Hydroquinone Versus Miconazol in Melasma
Unknown status
Hospital Central "Dr. Ignacio Morones Prieto"
Phase 4
2011-10-01
Melasma is an acquired discoloration of the skin characterized by brown colour changes
commonly on the face.The duration of this double-blind clinical trial will be 12 weeks. The
control group will receive treatment with topical Hydroquinone (4%), and the other group
topical miconazole. Miconazol has antimelanotic properties and can be used as treatment for
melasma patients. The estimated number of subjects to be recruited and randomized for the
study is at least 30. The purpose of this study is determine if there is a difference in the
effectiveness of these two agents. Melasma Area and Severity Index (MASI) score will be
assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry
and histological assessment will be also evaluated. Occurrence of adverse effects will also
be recorded.
Clinical Trial of Hydroquinone Versus Miconazol in Melasma
Unknown status
Universidad Autonoma de San Luis Potosí
Phase 4
2011-10-01
Melasma is an acquired discoloration of the skin characterized by brown colour changes
commonly on the face.The duration of this double-blind clinical trial will be 12 weeks. The
control group will receive treatment with topical Hydroquinone (4%), and the other group
topical miconazole. Miconazol has antimelanotic properties and can be used as treatment for
melasma patients. The estimated number of subjects to be recruited and randomized for the
study is at least 30. The purpose of this study is determine if there is a difference in the
effectiveness of these two agents. Melasma Area and Severity Index (MASI) score will be
assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry
and histological assessment will be also evaluated. Occurrence of adverse effects will also
be recorded.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
